Maher S, Wynne K, Zhernovkov V, Halasz M
Sci Data. 2024; 11(1):1111.
PMID: 39389992
PMC: 11467210.
DOI: 10.1038/s41597-024-03965-y.
Ferraguti G, Terracina S, Tarani L, Fanfarillo F, Allushi S, Caronti B
Curr Issues Mol Biol. 2024; 46(2):965-989.
PMID: 38392180
PMC: 10888178.
DOI: 10.3390/cimb46020062.
Parvin S, Akter J, Takenobu H, Katai Y, Satoh S, Okada R
BMC Cancer. 2023; 23(1):313.
PMID: 37020276
PMC: 10077671.
DOI: 10.1186/s12885-023-10772-y.
Yang T, Li J, Zhuo Z, Zeng H, Tan T, Miao L
iScience. 2022; 25(7):104655.
PMID: 35811845
PMC: 9263519.
DOI: 10.1016/j.isci.2022.104655.
Lin N, Chen S, Chang H, Lu M, Yang Y, Chou S
Oncogenesis. 2022; 11(1):8.
PMID: 35169131
PMC: 8847342.
DOI: 10.1038/s41389-022-00383-w.
The Neurotrophin Receptor TrkC as a Novel Molecular Target of the Antineuroblastoma Action of Valproic Acid.
Dedoni S, Marras L, Olianas M, Ingianni A, Onali P
Int J Mol Sci. 2021; 22(15).
PMID: 34360553
PMC: 8346142.
DOI: 10.3390/ijms22157790.
Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F
Med Res Rev. 2020; 41(2):961-1021.
PMID: 33155698
PMC: 7906923.
DOI: 10.1002/med.21750.
Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia.
Lebedev T, Vagapova E, Popenko V, Leonova O, Spirin P, Prassolov V
Front Oncol. 2019; 9:1046.
PMID: 31681584
PMC: 6813278.
DOI: 10.3389/fonc.2019.01046.
Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma.
Seo E, Kim J, Ma Y, Cho H, Ju H, Lee S
J Korean Med Sci. 2019; 34(39):e254.
PMID: 31602824
PMC: 6786962.
DOI: 10.3346/jkms.2019.34.e254.
Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells.
Hirano T, Nagasaki-Maeoka E, Ishizuka Y, Takatori A, Watanabe Y, Hoshi R
Med Oncol. 2019; 36(8):66.
PMID: 31183633
DOI: 10.1007/s12032-019-1289-6.
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta H, Macy M
Drug Des Devel Ther. 2018; 12:3549-3561.
PMID: 30425456
PMC: 6204873.
DOI: 10.2147/DDDT.S147384.
EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z, Takenobu H, Setyawati A, Akita N, Haruta M, Satoh S
Oncogene. 2018; 37(20):2714-2727.
PMID: 29507419
PMC: 5955864.
DOI: 10.1038/s41388-018-0133-3.
-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.
Dzieran J, Garcia A, Westermark U, Henley A, Sanchez E, Trager C
Proc Natl Acad Sci U S A. 2018; 115(6):E1229-E1238.
PMID: 29374092
PMC: 5819392.
DOI: 10.1073/pnas.1710901115.
Spontaneous regression of neuroblastoma.
Brodeur G
Cell Tissue Res. 2018; 372(2):277-286.
PMID: 29305654
PMC: 5920563.
DOI: 10.1007/s00441-017-2761-2.
Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation.
Ferlemann F, Menon V, Condurat A, Rossler J, Pruszak J
Sci Rep. 2017; 7(1):13612.
PMID: 29051534
PMC: 5648761.
DOI: 10.1038/s41598-017-13497-8.
Research progress of neuroblastoma related gene variations.
Cao Y, Jin Y, Yu J, Wang J, Yan J, Zhao Q
Oncotarget. 2017; 8(11):18444-18455.
PMID: 28055978
PMC: 5392342.
DOI: 10.18632/oncotarget.14408.
Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A, Takatori A, Hossain M, Hasan M, Tagawa M, Nagase H
Cancer Sci. 2016; 107(9):1223-32.
PMID: 27357360
PMC: 5021041.
DOI: 10.1111/cas.13003.
The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.
Ratner N, Brodeur G, Dale R, Schor N
Ann Neurol. 2016; 80(1):13-23.
PMID: 27043043
PMC: 5419586.
DOI: 10.1002/ana.24659.
Neurotrophin signaling in cancer stem cells.
Chopin V, Lagadec C, Toillon R, Le Bourhis X
Cell Mol Life Sci. 2016; 73(9):1859-70.
PMID: 26883804
PMC: 11108437.
DOI: 10.1007/s00018-016-2156-7.
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R, Wehrmann L, Golden R, Naraparaju K, Croucher J, MacFarland S
Cancer Lett. 2016; 372(2):179-86.
PMID: 26797418
PMC: 4792275.
DOI: 10.1016/j.canlet.2016.01.018.